Eli Lilly and Company (LLY)
Pre-market:
| Previous close | 920.89 |
| Open | 924.31 |
| Bid | 935.00 x 900 |
| Ask | 942.66 x 1200 |
| Day's range | 918.63 - 937.62 |
| 52-week range | 516.57 - 972.53 |
| Volume | |
| Avg. volume | 3,214,548 |
| Market cap | 841.916B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 115.01 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.56%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments.
- PR Newswire
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections. The data were published in The Lancet and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.
- PR Newswire
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve). The data were published in The New England Journal of Medicine (NEJM) and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.
